International Journal of Clinical Research

Objective To analyze the effect of aripiprazole combined with paroxetine in the clinical treatment of schizophrenia and the status of glucose metabolism during the treatment. Methods A total of 100 patients with schizophrenia who came to our hospital for treatment from January 2019 to March 2022 were selected as research objects, and were divided into control group (n=50) and observation group (n=50) by digital method. Patients in the control group were mainly treated with paroxetine hydrochloride tablets after admission, while patients in the observation group were treated with paroxetine hydrochloride. Aripiprazole tablets were used in combination therapy. After four weeks of clinical treatment, the clinical effects of the two groups of patients were compared, and the Negative and positive Symptom Scale (PANSS) score, cognitive Function Scale (CASI), various laboratory indicators and adverse reaction rate of the two groups of patients before and after treatment were compared. Results After four weeks of treatment, the overall effective rate was 74% in the control group and 94% in the observation group. After treatment, the total score of PANSS with negative symptoms and positive symptoms in both groups decreased significantly, and compared with the control group, the decrease range of patients in the observation group was significantly greater, the difference was significant (P < 0.05). After four weeks of drug treatment, the laboratory indexes of Zhang Zu patients were significantly increased, and compared with the control group, the indexes of patients in the observation group were significantly lower, the difference was significant (P < 0.05). Conclusion In the clinical treatment of schizophrenia, the combined treatment of aripiprazole and Paxil has more obvious efficacy, which can improve the cognitive function and clinical symptoms of patients, and has relatively little effect on the glucose metabolism of patients, with high safety.

Schizophrenia; Paroxetine; Aripiprazole; Glycolipid metabolism